AstraZeneca Bolsters Immunology Footprint with US$39 B Alexion Buyout

By Michelle Liu;

Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)

Published: 16 Dec-2020

DOI: 10.3833/pdr.v2020.i12.2579     ISSN: 1756-7874

Section: Mergers & Acquisitions



In order to bolster its immunology and rare disease pipeline, AstraZeneca (AZ) has agreed to purchase Alexion Pharmaceuticals for a total consideration of US$39 B...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details